Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND study of intrathecal CMP-002 in children with SYNGAP1-related disorder
2026-526220-46-00Phase 2Authorised
- Sponsor
- CAMP4 Therapeutics
- Start
- Oct 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of CMP-SYNGAP-01 in SYNGAP1-related disorders (2 arms), sponsored by CAMP4 Therapeutics. Primary endpoints: Incidence of adverse events including dose-limiting toxicities and Change from baseline in clinical laboratory results. Planned start Oct 2026; status: authorised.
02
Drugs
CMP-SYNGAP-01
03
Conditions
SYNGAP1-related disorders
Beyond the preview
Go deeper on 2026-526220-46-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526220-46-00.